Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.70 |
| ▸ | RAB9A | P51151 | 6/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.45 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106090 | 0.94 | IRAK4 (0.69) | IRAK4RAB9ANPC1GAA | |
| SCHEMBL16896618 | 0.88 | IRAK4 (0.61) | IRAK4RAB9ANPC1GAA | |
| SCHEMBL29662196 | 0.88 | IRAK4 (0.61) | IRAK4RAB9ANPC1GAA | |
| SCHEMBL16907800 | 0.88 | IRAK4 (0.59) | IRAK4RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL29662233 | 0.88 | IRAK4 (0.59) | IRAK4RAB9ANPC1SMN1; SMN2GAA | |
| SCHEMBL14824533 | 0.84 | IRAK4 (0.72) | IRAK4RAB9ANPC1KMT2ADUSP3 | |
| SCHEMBL14811263 | 0.84 | IRAK4 (0.54) | IRAK4RAB9ANPC1KMT2ADUSP3 | |
| SCHEMBL16896435 | 0.84 | IRAK4 (0.59) | IRAK4RAB9ANPC1GAA | |
| SCHEMBL29662205 | 0.84 | IRAK4 (0.59) | IRAK4RAB9ANPC1GAA | |
| SCHEMBL14809885 | 0.82 | IRAK4 (0.56) | IRAK4RAB9ANPC1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2020-03-05 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2017-02-09 | — | — | US | disclosed |
| WO-2013042137-A1 | BICYCLIC HETEROCYCLES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
| WO-2013042137-A1 | BICYCLIC HETEROCYCLES AS IRAK4 INHIBITORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2013-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885RAB9A 3342/4885NPC1 2062/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885RAB9A 3109/4885NPC1 2447/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885RAB9A 3342/4885NPC1 2062/4885 |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | IRAK4 2/4885RAB9A 3342/4885NPC1 2062/4885 |
| US-20170035881-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885RAB9A 3475/4885NPC1 2793/4885 |
| US-20200069668-A1 | Therapeutic Combinations of an IRAK4 Inhibitor and a BTK Inhibitor | IRAK4, IRAK1, IRAK2 | IRAK4 1/4885RAB9A 3475/4885NPC1 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.